Organisation paid for research Program year 2025 Source: CMS Open Payments

Citrials

Neither a doctor nor a teaching hospital

Research payments

$1,204,735

227 payments

Through program year 2025, Citrials is reported as receiving $1,204,735 in research payments, across 227 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $225,879 64
2024 Research $110,705 8
2023 Research $130,083 64
2022 Research $9,093 16
2021 Research $583,387 37
2020 Research $23,804 9
2019 Research $121,782 29

Breakdown

Who paid Research payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $721,066 21 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $325,445 31 payments
  3. BioXcel Therapeutics, Inc. $76,946 11 payments
  4. E.R. Squibb & Sons, L.L.C. $55,500 1 payment
  5. Boehringer Ingelheim Pharma GmbH & Co.KG $6,925 2 payments
  6. Boehringer Ingelheim International GmbH $5,216 33 payments
  7. Boehringer Ingelheim Canada Ltd.Ltee $3,777 16 payments
  8. Boehringer Ingelheim RCV GmbH & Co KG $3,236 18 payments
  9. Sumitomo Pharma America, Inc. $3,181 58 payments
  10. AbbVie, Inc. $1,582 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 2B Randomized, Double-Blind, Placebo- and Active-Controlled Trial of the Efficacy and Safety of MK-8189 in Participants Experiencing an Acute Episode of Schizophrenia $595,145 9 payments
  2. PoCC study in patients with PTSD $128,533 5 payments
  3. A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of suvorexant MK-4305 for the Treatment of Sleep Disturbance in Patients with Alzheimer s Disease $118,401 6 payments
  4. Bxcl501401 $76,946 11 payments
  5. Connex-2 $72,653 24 payments
  6. A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder $70,126 41 payments
  7. An 8-week Open-label, Multicenter Randomized Study of Accelerated and Slower Switching to Xanomeline/Trospium Following Atypical Antipsychotic Treatment to Assess the Safety, Tolerability, and Efficacy in Participants with DSM-5 Schizophrenia $55,500 1 payment
  8. Connex 2 $41,061 4 payments
  9. Connex-X $21,490 3 payments
  10. A Phase 2B Randomized, Double-Blind, Placebo- and Active-Controlled Trial of the Efficacy and Safety of MK-8189 in Participants Experiencing an Acute Episode of Schizophrenia $7,520 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record